Compound 21is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke
Journal of Hypertension, Volume 33, No. 1, Year 2015
Notification
URL copied to clipboard!
Introduction: Angiotensin II type 2 receptor (AT2R) stimulation is neuroprotective after experimental stroke. However, the therapeutic utility of AT2R stimulation has been hampered by the lack of a specific agonist with favourable bioavailability. Compound 21 (C21) - the first non-peptide AT2R agonist - offers a potential option to enhance stroke recovery. This study aimed to investigate the effect of C21 administration on early and late stroke outcomes, and the molecular mediators involved.